The promi­nent biotech founder and re­searcher David Saba­ti­ni has re­signed his tenured spot on MIT’s fac­ul­ty.

Saba­ti­ni stepped down fol­low­ing an ex­ter­nal probe that found he had vi­o­lat­ed the sex­u­al ha­rass­ment poli­cies of MIT’s White­head In­sti­tute, ac­cord­ing to a pub­lic let­ter from MIT pres­i­dent L. Rafael Reif. Saba­ti­ni was pre­vi­ous­ly oust­ed from White­head af­ter the probe’s find­ings, but the lat­est de­vel­op­ment saw him leave MIT al­to­geth­er.

Ac­cord­ing to Reif’s let­ter, “Pro­fes­sor Saba­ti­ni en­gaged in a sex­u­al re­la­tion­ship with a per­son over whom he held a ca­reer-in­flu­enc­ing role, he did not dis­close the re­la­tion­ship at any time to his su­per­vi­sors, and he failed to take any steps to re­lin­quish his men­tor­ing and ca­reer-in­flu­enc­ing roles, as the pol­i­cy re­quires.”

Ad­di­tion­al­ly, Reif wrote, Saba­ti­ni re­signed “with­out ex­er­cis­ing his pol­i­cy right to re­quest that a fac­ul­ty com­mit­tee be formed to re­view the rec­om­men­da­tion to re­voke tenure and re­port to me on their find­ings and rec­om­men­da­tion.”

A spokesper­son for the White­head In­sti­tute de­clined com­ment to End­points News. Saba­ti­ni could not be reached.

Last Au­gust, an in­de­pen­dent in­ves­ti­ga­tion dis­cov­ered the vi­o­la­tions, prompt­ing Saba­ti­ni’s ex­pul­sion from White­head and MIT to place him on ad­min­is­tra­tive leave. The in­quiry had been prompt­ed by a March 2021 sur­vey as­sess­ing the in­sti­tute’s cul­ture, a copy of which was pre­vi­ous­ly ob­tained by End­points.

The sur­vey “iden­ti­fied is­sues of par­tic­u­lar con­cern in the Saba­ti­ni lab,” White­head di­rec­tor Ruth Lehmann said at the time.

In re­sponse to his ouster, Saba­ti­ni filed a defama­tion law­suit against his ac­cuser last Oc­to­ber which claimed he had a con­sen­su­al sex­u­al re­la­tion­ship with a fel­low at the White­head In­sti­tute that was “ef­fec­tive­ly over” by 2019. Saba­ti­ni al­so said in the suit that the ac­cuser want­ed to “ex­act re­venge” af­ter he end­ed the re­la­tion­ship.

The ac­cuser filed a coun­ter­claim in De­cem­ber, al­leg­ing Saba­ti­ni’s suit amount­ed to a smear cam­paign. Saba­ti­ni al­leged­ly con­doned a “tox­ic and sex­u­al­ly charged lab en­vi­ron­ment,” the coun­ter­suit said and co­erced her in­to a non-con­sen­su­al sex­u­al re­la­tion­ship.

Saba­ti­ni’s res­ig­na­tion comes as sev­er­al promi­nent in­di­vid­u­als in bio­phar­ma have faced sex­u­al ha­rass­ment ac­cu­sa­tions in re­cent months. Mon­cef Slaoui ac­cept­ed re­spon­si­bil­i­ty for mis­con­duct that spurred an in­ves­ti­ga­tion at GSK, Josh Smi­ley was fired from his job as CFO at Eli Lil­ly and re­searcher Aubrey de Grey was fired af­ter al­le­ga­tions he ha­rassed two col­leagues.

The FDA hasn’t detected any potential safety signals, including for stroke, in people aged 65 years and older who have received Pfizer’s bivalent Covid booster, one senior official told members of the agency’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Thursday.

The update comes as the FDA and CDC investigate a “preliminary signal” that may indicate an increased risk of ischemic stroke in older Americans who received Pfizer’s updated shot.

The FDA has stopped use of another drug as a result of the new coronavirus variants. On Thursday, the agency announced that AstraZeneca’s antibody combo Evusheld, which was an important prevention option for many immunocompromised people and others, is no longer authorized.

The FDA said it made its decision based on the fact that Evusheld works on fewer than 10% of circulating variants.

Evusheld was initially given emergency authorization at the end of 2021. However, as Omicron emerged, so did studies that showed Evusheld might not work against the dominant Omicron strain. In October, the FDA warned healthcare providers that Evusheld was useless against the Omicron subvariant BA.4.6. It followed that up with another announcement earlier this month that it did not think Evusheld would work against the latest Omicron subvariant XBB.1.5.

Contract manufacturer Abzena has permanently laid off 66 employees at one of its San Diego sites, marking the latest in a string of layoffs spanning the biotech industry.

The layoffs took effect on Jan. 11 at the company’s 8810 Rehco Road site, according to a WARN notice filed with the Employment Development Department of California.

Abzena does have another location in the San Diego area, where the manufacturer invested $60 million and added 50,000 square feet in 2020. Endpoints News reached out to Abzena but has not received a response as of press time.

Magenta Therapeutics is pausing an early-stage clinical trial after a patient died. The death was deemed to be possibly related to its drug, MGTA-117.

The biotech said the pause of the Phase I/II trial is voluntary and gives it time to review all available data before deciding what to do next. It’s also reported the known information to the FDA.

The dose-escalation trial was designed to test whether MGTA-117, an antibody-drug conjugate, could serve as a more targeted alternative to high-intensity chemotherapy as a conditioning agent for cancer patients who are set to receive a stem cell transplant. It recruited patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.